Amerimmune Announces Filing of New Patent Application

Amerimmune Announces Filing of New Patent Application

Business Wire - October 7, 2002

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Oct. 7, 2002--Amerimmune Pharmaceuticals, Inc. (OTCBB:AMUN), announced that it has filed a patent application to protect the company's intellectual property for an investigational monoclonal antibody to treat patients suffering from human immunodeficiency virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS). The newly filed patent application, a result of the company's ongoing clinical research and development program, is believed to be important to the protection of the company's overall drug development program and its potential advantage to HIV/AIDS patients. However, there can be no assurance that a patent will be granted or that, if granted, this patent will be effective in protecting the company's intellectual property. To maintain its competitive advantage, the company will refrain from presenting details until the findings are published by the U.S. Patent and Trademark Office.

Amerimmune is aware that it will be difficult to continue the development of this product without an infusion of investor capital and/or building a relationship with a major partner already established in the field of HIV/AIDS drug development and is actively seeking such a collaborative partner.

About Amerimmune Pharmaceuticals, Inc.

Amerimmune is engaged in pharmaceutical research and development with the primary purpose of developing an investigational agent designed to protect the immune system, especially in patients suffering from HIV/AIDS. Amerimmune's intellectual property involves a monoclonal antibody that blocks certain adhesion molecules on one of the disease-fighting cells of the immune system, thereby protecting the immune system from "killer-type" T cells that tend to turn the human immune system against itself. By helping to shore up the immune system's natural defenses, this is a distinctly different therapeutic approach from antiviral drugs (e.g., reverse transcriptase inhibitors and protease inhibitors), which take the offensive against the virus. The company believes that this may be an important drug for the growing number of patients who have not been receiving treatment and for those who are on multi-drug therapy but have become resistant or intolerant to drugs currently used to treat HIV/AIDS.

For more information, please visit the company's Web site, www.amerimmune.com.

Statements made in this news release that are not historical facts, such as the preliminary results of clinical trials, may constitute "forward-looking statements," which are made pursuant to the safe harbor provisions in the federal securities laws. Forward-looking statements are subject to risks, uncertainties and other factors beyond the control of the company that could cause actual results to differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. Factors that could cause actual results to differ materially from the company's expectations are detailed in the company's filings with the Securities and Exchange Commission, including the company's Annual Report on Form 10-KSB but include: (i) the uncertain and unpredictable results of both preliminary and large-scale clinical trials, including the possibility that later clinical trials will contradict or not support the results of the company's Phase 1 human clinical trials, (ii) the difficulties of obtaining FDA and other regulatory approvals and the costs and other difficulties of complying with applicable regulatory restrictions even if such approvals can be obtained, (iii) the company's lack of operating history and financial resources, (iv) uncertainty as to the effectiveness of the company's protections of the intellectual property owned or licensed by it as well as the possibility of claims or challenges to the company's rights to critical intellectual property or technology, (v) the unavailability of sources of financing for the company's operations, (vi) competition within the pharmaceutical industry, (vii) the rapidly changing nature of technology and treatment methodology within the pharmaceutical and medical industries, and (viii) acceptance of any products developed by the company by medical professionals, medical insurers and others. The company disclaims any obligation to revise any forward-looking statements to reflect events or circumstances after the date of such statement or to reflect the occurrence of anticipated or unanticipated events.

CONTACT: THE BERLIN GROUP, INC. Lawrence Delaney Jr., 714/734-5000 amun.ir@berlingroup.com

SOURCE: Amerimmune Pharmaceuticals, Inc.

021007
BW021001

Copyright © 2002 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .